Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in tuft cells | 0.75 |
| chemistry Open Targets | compounds already reach it: izorlisib, vs-5584, buparlisib +27 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 301 | 0.91 |
| pathways Reactome | 9 pathways; mostly growth signalling | 0.60 |
Knock down and overexpress PIK3CG in microglia; measure phospho-ERK and phospho-AKT response to GDNF and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- phospho-ERK and phospho-AKT response to GDNF
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves phospho-ERK by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PIK3CG in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: phospho-ERK and phospho-AKT response to GDNF; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PIK3CG in dopamine neurons, braak+0.23 (p 0.549) → -0.07 (p 0.859)receipt 6335
- PIK3CG in microglia, braak+0.23 (p 0.545) → +0.26 (p 0.502)receipt 6334
Swarm cases
receipt 6335: PIK3CG in dopamine neurons, braak
- power
- full sample -0.06 (p 0.814, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.658, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.781, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.06, sign flips 2; without severely affected donors -0.06 (p 0.814, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PIK3CG in dopamine neurons.
case closed: nothing better to follow up.
receipt 6334: PIK3CG in microglia, braak
- power
- full sample +0.24 (p 0.346, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.18 (p 0.476, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.19 (p 0.439, n 18). could be the mix.
- skeptic
- leave-one-out range +0.13 to +0.42, sign flips 0; without severely affected donors +0.24 (p 0.346, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PIK3CG in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts